Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (January 2023)
34 slides from Immunome's investor presentation, January 2023
Slide 1: Harnessing the Power of the Human Memory B Cell
Harnessing the Power of the Human Memory B Cell JANUARY 2023 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | immunome.com Copyright © 2023 Immunome, Inc. All rights reserved.
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements This presentation includes certain disclosures that contain “forward-looking statements” All statements contained in this presentation are made as of the date specified on the cover, intended to qualify for the “safe harbor” from liability established by th
Slide 3: Immunome "At a Glance"
Immunome “At a Glance” Disruptive Technology Leveraging Human Immune Response Patient Informed Drug → Interrogates memory B cells, the most educated component of the human immune system Discovery Engine → Potential across multiple therapeutic areas Significant Partnering → AbbVie multi-year research
Slide 4: Strategic Discovery Collaboration with AbbVie
Strategic Discovery Collaboration with AbbVie AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets → Immunome will grant AbbVie the option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from three specified tumor types Immuno
Slide 5: B cells: Critical Players in Immunity
B cells: Critical Players in Immunity → B cell infiltration more closely associated with survival than T cell presence in multiple cancers Oncology → Success of I/O therapies appears to be associated with coordinated response including B cells and TLS in the unique context of each patient’s tumor mi
Slide 6: Cataloging the Context-Dependent B-cell Response Against Cancer
Cataloging the Context-Dependent B-cell Response Against Cancer DENDRITIC CELL MACROPHAGE → Cancer cells modify their microenvironment to NON-SILENT GENE MUTATIONS make it fertile ground for tumor growth ABBERANT GLYCOSYLATION → The human immune system makes a coordinated, B CELL ECTOPIC EXPRESSION
Slide 7: We See the Disease Through the Lens of a Memory B-cell
We See the Disease Through the Lens of a Memory B-cell Interrogate Most Educated Components of Immune Response in an Unbiased Manner at Industrial Scale Multiple Patients Ongoing access to new and Blood, Lymph nodes diverse patient memory B cells and tumor tissue Immortalizing B-cell Response Propri
Slide 8: Broad Applicability Across Therapeutic Areas
Broad Applicability Across Therapeutic Areas Unbiased Interrogation Unveils Targets & Underexplored Biology: Examples Oncology: Infectious Disease: Immunology: Target Rich Clusters Multi-modal Action Conserved Epitopes Targets identified across Unique insights into breadth Identification of antibodi
Slide 9: Platform has Potential for Diversified Partnering Strategy
Platform has Potential for Diversified Partnering Strategy Across Therapeutic Areas 01 02 03 04 05 Oncology Neurology → Neuroinflammation Oncology, Hematological Immune Disorders → Various Malignancies → Immunology → Auto-Immune Disorders Anti-Infectives Solid Tumors IMM-BCP-01 (SARS-CoV-2 Antibody
Slide 10: Immunome Pipeline
Immunome Pipeline Targets Identified from Authentic Human Immune Response POTENTIAL DISEASE PROGRAM OF RELEVANCE STAGE NEXT MILESTONE CLINICAL IMM-BCP-01 (Anti SARS-CoV-2)* Actively exploring Three antibody cocktail (multi-modal action, including COVID-19 Phase 1b* partnerships neutralization and co
Slide 11: Oncology
Oncology Copyright © 2023 Immunome, Inc. All rights reserved.
Slide 12: Immunome's Discovery Engine
Immunome’s Discovery Engine Functional B-cell Interrogation to Actionable Public Targets Memory B Cells Represent One of the Most Educated Components of the Human Immune System 01 02 03 B cells identify important Discovery Engine Functional screening targets within the natural interrogates patient p
Slide 13: Unveiling "Tumor Context" Target Clusters
Unveiling “Tumor Context” Target Clusters Novel Insights into Tumor Targets and Biological Processes Immune Modulation Human immune system sees unique features Novel Targets Discovery of cancer cells Extracellular Engine Matrix → Mutations, Unexpected localization of proteins (ectopic expression) on
Slide 14: Discovery Engine Highlights Ectopically Expressed Targets
Discovery Engine Highlights Ectopically Expressed Targets A Novel Class of Targets with Potentially High Tumor Selectivity High Throughput Functional Characterization: Proof of Concept → Some proteins normally found intracellularly appear to be Copyright © 2023 Immunome, Inc. All rights reserved. se
Slide 15: Example of an Ectopically Expressed Target as an ADC
Example of an Ectopically Expressed Target as an ADC Selective Tumor Cell Ab Highly Selective for Binding Single 17.Protein Target PR121-00372 40 Target B C11orf68 30 S-Score 20 10 0 0 00 00 00 00 10 20 30 40 Copyright © 2023 Immunome, Inc. All rights reserved. Raw Binding Signal Internalization Hig
Slide 16: IMM-ONC-01 Anti IL-38 Antibody
IMM-ONC-01 Anti IL-38 Antibody Copyright © 2023 Immunome, Inc. All rights reserved.
Slide 17: IMM-ONC-01 Anti IL-38 Antibody
IMM-ONC-01 Anti IL-38 Antibody Immune Modulation Novel Anti IL-38 Antibody Therapy has Potential to Be an Important Advancement in Cancer Care Targets Discovery Extracellular Engine Matrix IL-38 Appears to Suppress Anti-Tumor Immunity 01 02 03 04 IL-38, a novel cancer IL-38 dampens Blocking IL-38 le
Slide 18: Growing Evidence of IL-38 as a Key Immune Modulator
Growing Evidence of IL-38 as a Key Immune Modulator Copyright © 2023 Immunome, Inc. All rights reserved. &\WRNLQH % 3 - % * journal homepage: www.elsevier.com/locate/cytokine " ! Takeda et al. PLoS One (2017) # $ % & ' ( ) - $ # % $ ! " * ./ 0 1 * 0 , 2 - 3 1 + 03 * 3 40 + 4 0 5 % 4 10 0 54 2 03 % *
Slide 19: IL-38 is Expressed in Multiple Tumors
19 Copyright © 2023 Immunome, Inc. All rights reserved. 3. 2. 1. log2TPM log2TPM 25% 23% Bladder Head & Neck Immunome Internal Data Source: Tempus Real-World Data Skin 53% 14% Esophagus (% of Patient Expression) 30% Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset 41% Prostate Lung, Squ
Slide 20: IL-38 Expression is Associated with Reduced Immune Cell Infiltration
IL-38 Expression is Associated with Reduced Immune Cell Infiltration IL-38 Overexpression Inhibits Infiltration High IL-38 Expression is Associated with Reduced of T cells into Tumors In Vivo Immune Cell Infiltration* → IL-38 high tumor samples correlate with reduced infiltration of multiple immune
Slide 21: Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models
IMM-ONC-01 Anti IL-38 Antibody Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models1 Demonstration of Anti-Tumor Activity Induction of Anti-Tumor Memory (B16F10 Model) (EMT6 Model) → Immunologically cold tumor model → ~40% response rate upon treatment with IMM-ONC-01 → IMM-ONC-01 sign
Slide 22: IL-38 and Potential Combinations
IL-38 and Potential Combinations Mechanistic Rationales for Both Chemotherapy and Immune Checkpoint Combinations Tumor Cells Can Secrete IL-38 Upon IL-38 Levels Correlate with PD-L1 Expression Apoptosis Induction → PD-L1 positive cases exhibited higher levels of IL-38 expression → IL-38 secretion as
Slide 23: IMM-ONC-01 Program Summary
IMM-ONC-01 Program Summary Targets IL-38, a Novel Immune Modulator → In vitro and in vivo preclinical research confirms antitumor IL-38 Protein Expression In HNSCC Aligns activity of ONC-01 in solid tumors as a monotherapy With Transcriptional Data2 → Gene expression profiling of patient tumors sugg
Slide 24: Oncology Platform and Research Pipeline
ONCOLOGY Platform and Research Pipeline Copyright © 2023 Immunome, Inc. All rights reserved.
Slide 25: Untapped Biology and Novel Therapeutic Targets
Untapped Biology and Novel Therapeutic Targets Current Therapies are Based on Limited Knowledge of the Diversity and Complexity of Human Tumors HER2 TROP2 TOMORROW Copyright © 2023 Immunome, Inc. All rights reserved. TODAY EGFR Novel targets have the potential to lead to CD20 more effective antibody
Slide 26: IMM20059 Anti-EPN1 Antibody
IMM20059 Anti-EPN1 Antibody Immune Modulation Novel Antibody Targeting Ectopically Expressed Protein Targets Discovery Extracellular Engine Matrix 01 02 03 04 EPN1, a novel cancer EPN1 ectopically Impact of targeting Preclinical efficacy target, identified by expressed on surface ectopic EPN1: testi
Slide 27: Anti-EPN1 Antibody in Combination with PD-L1 Enhances Anti-Tumor Efficacy
Anti-EPN1 Antibody in Combination with PD-L1 Enhances Anti-Tumor Efficacy1 Tumor Growth Anti-tumor Immune Response → Combination of IMM20059 + atezolizumab leads to significant → IMM20059 + atezolizumab treatment of B16.F10 tumor-bearing tumor control in the B16.F10 model as compared to either mice
Slide 28: Immunome Discovery Engine 2.0: Context Dependent Drug Discovery
Immunome Discovery Engine 2.0: Context Dependent Drug Discovery Beyond Memory B-cells: What Other Immune Components Play a Role in Response? Understanding The Interplay Between the Tumor and its Microenvironment 01 02 03 04 Capture immune responses Multi-dimensional Leverage big data sets and Correl
Slide 29: Financial Overview and Intellectual Property Snapshot
Financial Overview and Intellectual Property Snapshot → Cash at least through 3Q 2024 → Capital efficient business model – partnerships and proprietary programs → Eligible for additional platform access payments during the research term in the AbbVie Collaboration Platform technology and discovery e
Slide 30: Immunome "At a Glance"
Immunome “At a Glance” Disruptive Technology Leveraging Human Immune Response Patient Informed Drug → Interrogates memory B cells, the most educated component of the human immune system Discovery Engine → Potential across multiple therapeutic areas Significant Partnering → AbbVie multi-year research
Slide 31: IMM-BCP-01
IMM-BCP-01 Collaboration with U.S. DoD & DHA for IMM- BCP-01 Program, Awarded Up to $17.6M in Funding* Phase 1b Topline Results * OTA: W911QY-20-9-0019 Copyright © 2023 Immunome, Inc. All rights reserved.
Slide 32: IMM-BCP-01: Three Antibody Cocktail for the Treatment of COVID-19
IMM-BCP-01: Three Antibody Cocktail for the Treatment of COVID-19 01 02 03 04 PHASE 1B Identified Antibodies IMM-BCP-01 three In vitro preclinical In vitro neutralization from SARS-CoV-2 antibody cocktail neutralization of translates into in vivo patient memory designed to retain variants that have
Slide 33: IMM-BCP01-001 Clinical Study Top Line Results: Safety and Pharmacokinetics
IMM-BCP01-001 Clinical Study Top Line Results: Safety and Pharmacokinetics → Phase 1b, 2:1 randomization (n = 9; 6 active: 3 placebo) IMM-BCP-1001 - Mean Serum Concentration Comparison - Cohort 1 (ng/mL) 1000000 → Single dose of cocktail (600 mg total) 1000000 administered as an intravenous infusion
Slide 34: IMM-BCP-01 Neutralizes Virus Utilizing Different Mechanisms
IMM-BCP-01 Neutralizes Virus Utilizing Different Mechanisms ANTIBODY INDUCED CONFORMATIONAL Structural analysis demonstrates IMM20253 binding CHANGE DESTABILIZES SPIKE PROTEIN* induces unfolding of spike trimer 2 → Increasing antibody:trimer ratio results in dissociation of trimer into soluble antib